|
Post by straightly on Dec 13, 2017 10:23:57 GMT -5
Not to worry, the crop is growing...
|
|
|
Post by goyocafe on Dec 13, 2017 10:26:57 GMT -5
|
|
|
Post by joeypotsandpans on Dec 14, 2017 18:22:34 GMT -5
Volume has really dried up, as of yesterday largest clearing firm had no stock to lend (and yes I saw the loan rate thread), with volatility at extreme quiet levels and end of year approaching, the crickets you hear, (paint drying you see, grass growing, etc.) could soon be running when the noise hits looking forward to '18
|
|
|
Post by LosingMyBullishness on Dec 14, 2017 19:46:15 GMT -5
Volume has really dried up, as of yesterday largest clearing firm had no stock to lend (and yes I saw the loan rate thread), with volatility at extreme quiet levels and end of year approaching, the crickets you hear, (paint drying you see, grass growing, etc.) could soon be running when the noise hits looking forward to '18 Ahem.. and this does mean?
|
|
|
Post by seanismorris on Dec 14, 2017 20:23:03 GMT -5
It means come back in January, nothing to see here.
Happy Holidays!
|
|
|
Post by joeypotsandpans on Dec 14, 2017 20:28:46 GMT -5
Volume has really dried up, as of yesterday largest clearing firm had no stock to lend (and yes I saw the loan rate thread), with volatility at extreme quiet levels and end of year approaching, the crickets you hear, (paint drying you see, grass growing, etc.) could soon be running when the noise hits looking forward to '18 Ahem.. and this does mean? Essentially that this has been consolidating at this level for quite some time with relatively light volume. Considering the run-up on extreme volume and subsequent pull back and consolidation IMO it is setting up for it's next leg up. Short interest was at a record level as of 11/30, I suspect that hasn't changed much to this point. The short interest has continued to rise while the s/p has settled at a base in the $3.00 area. I believe fundamentals and s/p will improve (and the supply is way imbalanced should that happen) so I guess you can say I'm "intrinsically bullish" that things will be a lot nosier heading into and throughout the new year
|
|
|
Post by mnholdem on Dec 14, 2017 22:35:30 GMT -5
The Afrezza-OneDrop study may provide some welcome news in early 2018 when it completes collecting its data in February for the primary outcome measure: Primary Outcome Measures: - Hemoglobin A1c [ Time Frame: 3 months ]
- 3-month between-group change in A1c assessed by a central lab
Source: clinicaltrials.gov/ct2/show/NCT03313960?term=Mannkind&recrs=abdf&rank=3Estimated Enrollment: 400 Actual Study Start Date: October 5, 2017 Estimated Study Completion Date: February 1, 2019 Estimated Primary Completion Date: February 1, 2018 (Final data collection date for primary outcome measure)--- There's also the published results from the STAT trial to look forward to in early/mid 2018: Primary Outcome Measures: - Improved time in range (70-180 mg/dl) with TI on CGM [ Time Frame: 4 weeks ]
- Better post-prandial glucose excursion (1-4 hours after meals) with TI [ Time Frame: 4 weeks ]
Source: clinicaltrials.gov/ct2/show/NCT03143816?term=Mannkind&recrs=abdf&rank=4--- Still another trial under way is entitled "Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients" the purpose of which is "to examine the effects of adding prandial Afrezza inhaled insulin to patients with type 2 diabetes who are not controlled after at least 6 months of other diabetes treatments including oral agents, basal insulin, or GLP-1 use." Primary Outcome Measures: - Percentage change from baseline HbA1c [ Time Frame: 3 months ]
- Demonstrate that the addition of mealtime Afrezza can significantly lower HbA1c within 3 months in uncontrolled type 2 diabetes patients initially having HbA1c of 8 or higher, despite at least 6 months of prior therapy with diabetes medications.
Estimated Enrollment: 40 Actual Study Start Date: October 16, 2017 Estimated Study Completion Date: April 15, 2018 Estimated Primary Completion Date: April 15, 2018 (Final data collection date for primary outcome measure)Source: clinicaltrials.gov/ct2/show/NCT03324776?term=Mannkind&recrs=abdf&rank=2--- CEO Michael Castagna also stated at a recent conference that MannKind would be filing an IND for its Trepostinol (Technosphere) for pulmonary arterial hypertension (PAH) in early 2018. That will make headlines. 2018 is shaping up to be an event-filled year, possibly ending with the company releasing preliminary results from the Afrezza pediatric trial. Noise? I can already hear Sports shouting, "OMG! OMG!" and liane and brentie switching their avatars to cats doing somersaults and cartwheels.
|
|
|
Post by brentie on Dec 14, 2017 23:42:40 GMT -5
You must be thinking of somebody else. I would never do that.
|
|
|
Post by babaoriley on Dec 14, 2017 23:59:36 GMT -5
The Afrezza-OneDrop study may provide some welcome news in early 2018 when it completes collecting its data in February for the primary outcome measure: Primary Outcome Measures: - Hemoglobin A1c [ Time Frame: 3 months ]
- 3-month between-group change in A1c assessed by a central lab
Source: clinicaltrials.gov/ct2/show/NCT03313960?term=Mannkind&recrs=abdf&rank=3Estimated Enrollment: 400 Actual Study Start Date: October 5, 2017 Estimated Study Completion Date: February 1, 2019 Estimated Primary Completion Date: February 1, 2018 (Final data collection date for primary outcome measure)--- There's also the published results from the STAT trial to look forward to in early/mid 2018: Primary Outcome Measures: - Improved time in range (70-180 mg/dl) with TI on CGM [ Time Frame: 4 weeks ]
- Better post-prandial glucose excursion (1-4 hours after meals) with TI [ Time Frame: 4 weeks ]
Source: clinicaltrials.gov/ct2/show/NCT03143816?term=Mannkind&recrs=abdf&rank=4--- Still another trial under way is entitled "Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients" the purpose of which is "to examine the effects of adding prandial Afrezza inhaled insulin to patients with type 2 diabetes who are not controlled after at least 6 months of other diabetes treatments including oral agents, basal insulin, or GLP-1 use." Primary Outcome Measures: - Percentage change from baseline HbA1c [ Time Frame: 3 months ]
- Demonstrate that the addition of mealtime Afrezza can significantly lower HbA1c within 3 months in uncontrolled type 2 diabetes patients initially having HbA1c of 8 or higher, despite at least 6 months of prior therapy with diabetes medications.
Estimated Enrollment: 40 Actual Study Start Date: October 16, 2017 Estimated Study Completion Date: April 15, 2018 Estimated Primary Completion Date: April 15, 2018 (Final data collection date for primary outcome measure)Source: clinicaltrials.gov/ct2/show/NCT03324776?term=Mannkind&recrs=abdf&rank=2--- CEO Michael Castagna also stated at a recent conference that MannKind would be filing an IND for its Trepostinol (Technosphere) for pulmonary arterial hypertension (PAH) in early 2018. That will make headlines. 2018 is shaping up to be an event-filled year, possibly ending with the company releasing preliminary results from the Afrezza pediatric trial. Noise? I can already hear Sports shouting, "OMG! OMG!" and liane and brentie switching their avatars to cats doing somersaults and cartwheels. Darn, but you are one fundamental investor, MN!
|
|
|
Post by mnholdem on Dec 15, 2017 5:41:09 GMT -5
Just making some noise, my friend...it helps that new the management is better at planning and guidance, providing a better roadmap for stockholders and new investors to use in navigating this volatile stock. Speaking of new investors: NEW YORK, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 18, 2017. MNKD is among the 54 securities to be added next Monday. That just may be a good day for shorts to begin unwinding their positions. --- May the force be with you.
|
|
|
Post by agedhippie on Dec 15, 2017 8:14:07 GMT -5
J MNKD is among the 54 securities to be added next Monday. That just may be a good day for shorts to begin unwinding their positions. --- May the force be with you. What it may well do is provide a pool of new shares for the shorts since the trackers will lend out the stock they buy to track the IBB. I hope the ATM will be open for business so we can get some of the spend.
|
|
|
Post by cjc04 on Dec 15, 2017 10:50:22 GMT -5
J MNKD is among the 54 securities to be added next Monday. That just may be a good day for shorts to begin unwinding their positions. --- May the force be with you. What it may well do is provide a pool of new shares for the shorts since the trackers will lend out the stock they buy to track the IBB. I hope the ATM will be open for business so we can get some of the spend. I agree, with guaranteed buyers and a boatload of new shares, MNKD should be selling,,,, especially into a rise in sp.
|
|
|
Post by babaoriley on Dec 15, 2017 11:14:24 GMT -5
Damn, we're gonna rip right through the sound barrier getting to $10 by end of year - hold onto your hats, everyone, you're gonna need to be extending them (inverted) on street corners soon. Where's Mike K when we need him? Geez, why didn't we wait for $10 before selling those shares in early October?
Well, at least the market must be way down, how else could this be. What's that you say?
|
|
|
Post by buyitonsale on Dec 15, 2017 11:40:41 GMT -5
I thought we would see a sale after the vote and it's here.
I added.
Go MNKD!
|
|
|
Post by Omega on Dec 15, 2017 11:52:37 GMT -5
Just picked up half the shares I've been waiting to add.
|
|